These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 32149490)

  • 1. Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites.
    Olp MD; Sprague DJ; Goetz CJ; Kathman SG; Wynia-Smith SL; Shishodia S; Summers SB; Xu Z; Statsyuk AV; Smith BC
    ACS Chem Biol; 2020 Apr; 15(4):1036-1049. PubMed ID: 32149490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
    Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.
    Jung M; Philpott M; Müller S; Schulze J; Badock V; Eberspächer U; Moosmayer D; Bader B; Schmees N; Fernández-Montalván A; Haendler B
    J Biol Chem; 2014 Mar; 289(13):9304-19. PubMed ID: 24497639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational study on the selective inhibition mechanism of MS402 to the first and second bromodomains of BRD4.
    Wang Q; Li Y; Xu J; Wang Y; Shi D; Liu L; Leung EL; Yao X
    Proteins; 2019 Jan; 87(1):3-11. PubMed ID: 30260047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolically Derived Lysine Acylations and Neighboring Modifications Tune the Binding of the BET Bromodomains to Histone H4.
    Olp MD; Zhu N; Smith BC
    Biochemistry; 2017 Oct; 56(41):5485-5495. PubMed ID: 28945351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors.
    Ember SW; Zhu JY; Olesen SH; Martin MP; Becker A; Berndt N; Georg GI; Schönbrunn E
    ACS Chem Biol; 2014 May; 9(5):1160-71. PubMed ID: 24568369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure investigation, enrichment analysis and structure-based repurposing of FDA-approved drugs as inhibitors of BET-BRD4.
    Wakchaure P; Velayutham R; Roy KK
    J Biomol Struct Dyn; 2019 Aug; 37(12):3048-3057. PubMed ID: 30079805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular docking and dynamics simulation study of flavonoids as BET bromodomain inhibitors.
    Raj U; Kumar H; Varadwaj PK
    J Biomol Struct Dyn; 2017 Aug; 35(11):2351-2362. PubMed ID: 27494802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico study directed towards identification of novel high-affinity inhibitors targeting an oncogenic protein: BRD4-BD1.
    Tumdam R; Kumar A; Subbarao N; Balaji BS
    SAR QSAR Environ Res; 2018 Dec; 29(12):975-996. PubMed ID: 30411639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors.
    Karim RM; Bikowitz MJ; Chan A; Zhu JY; Grassie D; Becker A; Berndt N; Gunawan S; Lawrence NJ; Schönbrunn E
    J Med Chem; 2021 Nov; 64(21):15772-15786. PubMed ID: 34710325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity.
    Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P
    Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico design and molecular basis for the selectivity of Olinone toward the first over the second bromodomain of BRD4.
    Rodríguez Y; Gerona-Navarro G; Osman R; Zhou MM
    Proteins; 2020 Mar; 88(3):414-430. PubMed ID: 31587361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of novel ligand targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery: complete pharmacophore approach.
    Shanmugam V; Muthukrishnan S
    J Biomol Struct Dyn; 2023; 41(23):14524-14539. PubMed ID: 36841551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective inhibition of BET bromodomains.
    Filippakopoulos P; Qi J; Picaud S; Shen Y; Smith WB; Fedorov O; Morse EM; Keates T; Hickman TT; Felletar I; Philpott M; Munro S; McKeown MR; Wang Y; Christie AL; West N; Cameron MJ; Schwartz B; Heightman TD; La Thangue N; French CA; Wiest O; Kung AL; Knapp S; Bradner JE
    Nature; 2010 Dec; 468(7327):1067-73. PubMed ID: 20871596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
    Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
    J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective N-Terminal BET Bromodomain Inhibitors by Targeting Non-Conserved Residues and Structured Water Displacement*.
    Cui H; Divakaran A; Pandey AK; Johnson JA; Zahid H; Hoell ZJ; Ellingson MO; Shi K; Aihara H; Harki DA; Pomerantz WCK
    Angew Chem Int Ed Engl; 2021 Jan; 60(3):1220-1226. PubMed ID: 32975004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RVX-297- a novel BD2 selective inhibitor of BET bromodomains.
    Kharenko OA; Gesner EM; Patel RG; Norek K; White A; Fontano E; Suto RK; Young PR; McLure KG; Hansen HC
    Biochem Biophys Res Commun; 2016 Aug; 477(1):62-67. PubMed ID: 27282480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-based protein stabilization assays for the detection of interactions between small-molecule inhibitors and BRD4.
    Schulze J; Moosmayer D; Weiske J; Fernández-Montalván A; Herbst C; Jung M; Haendler B; Bader B
    J Biomol Screen; 2015 Feb; 20(2):180-9. PubMed ID: 25266565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantifying the Selectivity of Protein-Protein and Small Molecule Interactions with Fluorinated Tandem Bromodomain Reader Proteins.
    Kalra P; McGraw L; Kimbrough JR; Pandey AK; Solberg J; Cui H; Divakaran A; John K; Hawkinson JE; Pomerantz WCK
    ACS Chem Biol; 2020 Nov; 15(11):3038-3049. PubMed ID: 33138352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.